Claims for Patent: 10,933,034

Summary for Patent: 10,933,034

Title:	Bupropion as a modulator of drug activity
Abstract:	Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s):	Tabuteau; Herriot (New York, NY)
Assignee:	ANTECIP BIOVENTURES II LLC (New York, NY)
Application Number:	17/003,777
Patent Claims:	1. A method of treating depression, comprising administering: a bupropion, at a daily dose that is about 100 mg to about 200 mg, and a dextromethorphan, at a daily dose that is about 60 mg to about 100 mg, to a human being in need thereof for at least 8 consecutive days, wherein the bupropion and the dextromethorphan are administered in a dosage form containing both the bupropion and the dextromethorphan as the only therapeutically active compounds, wherein the dosage form is formulated for immediate release of dextromethorphan and sustained release of bupropion, and wherein administering the dosage form is more effective in treating depression than administering the same daily dose of the bupropion alone for at least 8 consecutive days. 2. The method of claim 1, wherein administering the dosage form is more effective in treating depression than administering the same daily dose of the dextromethorphan alone. 3. The method of claim 1, wherein the dosage form is administered once daily. 4. The method of claim 1, wherein the dosage form is administered twice daily. 5. The method of claim 1, wherein the dosage form is administered for at least 14 consecutive days. 6. The method of claim 1, wherein the dosage form is administered for at least 30 consecutive days. 7. The method of claim 1, wherein the dosage form has a weight ratio of the dextromethorphan to the bupropion that is about 0.3 to about 0.5. 8. The method of claim 1, wherein the dosage form is administered orally. 9. The method of claim 1, wherein the dosage form is in a solid form. 10. The method of claim 1, wherein on the eighth day, the human being has a C.sub.avg of bupropion that is at least about 10 ng/mL after the dosage form is administered. 11. The method of claim 1, wherein on the eighth day, the human being has a C.sub.max of bupropion that is at least about 90 ng/mL after the dosage form is administered. 12. The method of claim 1, wherein the human being has major depressive disorder.